Skip to main content

Table 5 Within- and between-group changes in metabolic syndrome variables over 12 weeks

From: Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial

 

Baseline

Week 12

Within-group mean change over 12 weeksa

Between-group mean change over 12 weeksb

Outcome

n

Mean ± SD

n

Mean ± SD

Mean (95% CI)

Mean (95% CI)

P

Waist circumference (cm)

 EXE

13

106.8 ± 14.2

13

105.6 ± 14.4

−1.2 (−3.3, − 1.0)

−3.7 (−6.6, − 0.8)

0.01

 NoEXE

19

97.9 ± 10.1

19

99.6 ± 12.4

2.0 (0.2, 3.7)

  

Systolic blood pressure (mm Hg)

 EXE

13

122.2 ± 14.2

13

122.4 ± 15.3

−1.4 (− 8.5, 5.7)

−5.1 (− 15.5, 5.3)

0.32

 NoEXE

19

128.8 ± 13.0

19

129.8 ± 14.0

2.1 (−3.8, 7.9)

  

Diastolic blood pressure (mm Hg)

 EXE

13

76.9 ± 9.2

13

75.4 ± 8.9

−1.9 (−6.3, 2.5)

− 0.5 (− 6.8, 5.8)

0.87

 NoEXE

19

79 ± 5.1

19

79.0 ± 8.6

0.3 (−3.3, 4.0)

  

HDL-C (mg/dL)

 EXE

13

46.5 ± 12.2

12

49.0 ± 19.0

3.8 (−1.9, 9.6)

6.1 (− 1.6, 13.8)

0.11

 NoEXE

19

61.3 ± 16.3

19

61.5 ± 18.4

− 0.3 (−4.8, 4.1)

  

Triglycerides (mg/dL)

 EXE

13

152.9 ± 65.4

12

148.7 ± 42.4

−3.7 (−31.9, 24.4)

−6.7 (− 46.7, 33.2)

0.73

 NoEXE

19

131.63 ± 63.7

19

130.2 ± 79.5

−3.6 (−25.8, 18.6)

  

Glucose (mg/dL)

 EXE

13

106.1 ± 33.0

13

103.7 ± 18.1

−4.0 (−9.8, 1.8)

− 4.7 (− 13.2, 3.8)

0.27

 NoEXE

19

104.5 ± 20.3

19

104.7 ± 20.4

−0.4 (−5.2, 4.4)

  

Insulin (mU/L)

 EXE

13

7.9 ± 7.6

12

5.5 ± 2.7

−1.3 (−5.6, 2.9)

−2.0 (−8.1, 4.0)

0.50

 NoEXE

19

4.9 ± 4.7

19

6.6 ± 9.2

0.9 (−2.4, 4.3)

  

HOMA-IR

 EXE

13

2.6 ± 4.2

12

1.4 ± 0.7

−0.6 (− 1.9, 0.6)

−0.7 (−2.5, 1.0)

0.39

 NoEXE

19

1.3 ± 1.5

19

1.8 ± 2.6

−0.01(−1.0, 1.0)

  
  1. Data presented as mean ± standard deviation. P, significance level; EXE, exercise groups (TRAINPRO and TRAIN); NoEXE, non-exercise groups (PRO and STRETCH); HDL-C; high-density lipoprotein cholesterol; HOMA-IR, homeostatic model of assessment of insulin resistance
  2. aEXE relative to NoEXE adjusted for baseline values
  3. bEXE relative to NoEXE adjusted for baseline values, protein supplementation, body mass index and number of comorbidities